| Identification | Back Directory | [Name]
2H-Indol-2-one, 1,3-dihydro-3-(4-hydroxyphenyl)-3-[4-(trifluoromethoxy)phenyl]-7-(trifluoromethyl)-, (3R)- | [CAS]
2407860-35-7 | [Synonyms]
ErSO
ErSo-DFP
2H-Indol-2-one, 1,3-dihydro-3-(4-hydroxyphenyl)-3-[4-(trifluoromethoxy)phenyl]-7-(trifluoromethyl)-, (3R)- | [Molecular Formula]
C22H13F6NO3 | [MOL File]
2407860-35-7.mol | [Molecular Weight]
453.33 |
| Chemical Properties | Back Directory | [Boiling point ]
485.0±45.0 °C(Predicted) | [density ]
1.461±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
9?+-.0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
ErSO is an activator of the unfolded protein response which eradicates human breast tumors in mice. ErSO activates the anticipatory unfolded protein response (a-UPR) and induces rapid and selective necrosis of ERα-positive breast cancer cell lines in vitro. In multiple orthotopic models, ErSO treatment given either orally or intraperitoneally for 14 to 21 days induced tumor regression without recurrence. In a cell line tail vein metastasis model, ErSO was also effective at inducing regression of most lung, bone, and liver metastases. ErSO treatment induced almost complete regression of brain metastases in mice carrying intracranial human breast cancer cell line xenografts. |
|
|